Changes in statin therapy eligibility under the 2026 versus 2018 dyslipidemia guidelines

Jared A. Spitz, Faith E. Metlock, Bede Nriagu, Carl Ade, Britton Scheuermann, Lily Dastmalchi, Garima Sharma, Samuel Kim · 2026

Read Changes in statin therapy eligibility under the 2026 versus 2018 dyslipidemia guidelines by Jared A. Spitz, Faith E. Metlock, Bede Nriagu, Carl Ade, Britton Scheuermann, Lily Dastmalchi, Garima Sharma, Samuel Kim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13633900.txt.

Description

Jared A. Spitz and seven colleagues published this 2026 analysis of how new cholesterol guidelines change who qualifies for statins in the United States. The 2026 guideline replaced the 2018 version and adopted a newer risk framework for prevention. Earlier guesses suggested eligibility might shrink. The team tested the full rule change on national survey data from 2017 to 2020, weighting results to represent the country.

Eligibility actually grew a great deal. The newly eligible group formed a large slice of adults aged thirty to seventy-nine, while only a small slice lost eligibility. The biggest relative jump came in adults under fifty. Older age, higher body mass, higher cholesterol, smoking, and hypertension all predicted newly qualifying. The authors say the wider net reflects the complete new framework, not the risk equations alone. Health systems now face the work of turning eligibility into actual treatment.

Catalog record

CREATORJared A. Spitz, Faith E. Metlock, Bede Nriagu, Carl Ade, Britton Scheuermann, Lily Dastmalchi, Garima Sharma, Samuel Kim
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48392
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13633900

Browse the full library · About the Tower of Babel